2. Signaling Pathways
  3. GPCR/G Protein
    Neuronal Signaling
  4. CGRP Receptor

CGRP Receptor

Calcitonin gene-related peptide receptor

CGRP Receptor

Related Products

PDF 0.39 MB

CGRP receptor is a heterodimer formed by calcitonin-receptor-like receptor (CRLR), a type II (family B) G-protein-coupled receptor, and receptor-activity-modifying protein 1 (RAMP1), a single-membrane-pass protein. RAMP1 is needed for CGRP binding and also cell-surface expression of CLR. CLR is an example of a family B GPCR.

CGRP is a neuropeptide abundant in the trigeminal system and widely expressed in both the peripheral and central nervous systems. CGRP has several functions including vasodilation, the perception of painful stimuli, and inflammation. CGRP exerts its biological action by interacting with its receptors. There are two types of CGRP receptors, CGRP-A and CGRP-B.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-10095
    Olcegepant
    		Antagonist 99.83%
    Olcegepant (BIBN-4096) is a potent and selective non-peptide antagonist of the calcitonin gene-related peptide 1 (CGRP1) receptor with IC50 of 0.03 nM and Ki of 14.4 pM for human CGRP.
    Olcegepant
  • HY-P0203A
    α-CGRP (mouse, rat) (TFA)
    		99.22%
    α-CGRP (mouse, rat) TFA, a neuropeptide (calcitonin gene-related peptide (CGRP)) mainly expressed in neuromuscular junction, is a potent vasodilator. α-CGRP (mouse, rat) TFA can lead to a fall in blood pressure and an increase in heart rate by peripheral administration, also relax colonie smooth muscle. α-CGRP (mouse, rat) TFA has the potential in cardiovascular, pro-inflammatory, migraine and metabolic studies.
    α-CGRP (mouse, rat) (TFA)
  • HY-P1071
    α-CGRP(human)
    		99.76%
    α-CGRP(human) is a regulatory neuropeptide of 37 amino acids. α-CGRP(human) is widely distributed in the central and peripheral nervous system. α-CGRP(human) is a potent vasodilator.
    α-CGRP(human)
  • HY-P3462A
    Cagrilintide acetate
    		Agonist 99.81%
    Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies.
    Cagrilintide acetate
  • HY-P0209
    Rat CGRP-(8-37)
    		Antagonist 99.37%
    Rat CGRP-(8-37) (VTHRLAGLLSRSGGVVKDNFVPTNVGSEAF) is a highly selective CGRP receptor antagonist.
    Rat CGRP-(8-37)
  • HY-P0090
    Calcitonin (salmon)
    		Agonist 99.41%
    Calcitonin salmon, a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption.
    Calcitonin (salmon)
  • HY-P1471
    Adrenomedullin (AM) (22-52), human
    		Antagonist 99.91%
    Adrenomedullin (AM) (22-52), human, an NH2 terminal truncated adrenomedullin analogue, is an adrenomedullin receptor antagonist, and also antagonizes the calcitonin generelated peptide (CGRP) receptor in the hindlimb vascular bed of the cat.
    Adrenomedullin (AM) (22-52), human
  • HY-P1548A
    β-CGRP, human TFA
    		99.42%
    β-CGRP, human TFA (Human β-CGRP TFA) is one of calcitonin peptides, acts via the complex of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP), with IC50s of 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2 in cells.
    β-CGRP, human TFA
  • HY-10095A
    Olcegepant hydrochloride
    		Antagonist 99.39%
    Olcegepant hydrochloride (BIBN-4096 hydrochloride) is a potent and selective non-peptide antagonist of the calcitonin gene-related peptide 1 (CGRP1) receptor with IC50 of 0.03 nM and with a Ki of 14.4 pM for human CGRP.
    Olcegepant hydrochloride
  • HY-19960
    BCTC
    		Inhibitor 98.03%
    BCTC is an orally active current inhibitor of vanilloid receptor type 1 (VR1). BCTC is a transient receptor potential cation channel subfamily M member 8 (TRPM8) and transient receptor potential vanilloid 1 (TRPV1) antagonist. BCTC is an insulin sensitizer and secretor. BCTC has anticancer and analgesic effects.
    BCTC
  • HY-P2273
    Calcitonin (human)
    		Agonist 99.70%
    Calcitonin (human) is a hypocalcemic hormone. Calcitonin can lower blood calcium levels and inhibit bone resorption. Calcitonin can be used in hypercalcemia or osteoporosis research.
    Calcitonin (human)
  • HY-12366
    Ubrogepant
    		Antagonist 99.69%
    Ubrogepant (MK-1602) is an orally active calcitonin gene-related peptide receptor (CGRP) antagonist with potential for use in acute migraine.
    Ubrogepant
  • HY-10301
    MK-3207
    		Antagonist 99.60%
    MK-3207 is an orally active, highly selective and species-specific CGRP receptor antagonist (for human CGRP receptor: IC50=0.12 nM; Ki=0.024 nM). MK-3207 can be used for migraine studies.
    MK-3207
  • HY-P1014
    HCGRP-(8-37)
    		Antagonist 98.05%
    HCGRP-(8-37) is a human calcitonin gene-related peptide (hCGRP) fragment and also an antagonist of CGRP receptor.
    HCGRP-(8-37)
  • HY-32709
    Telcagepant
    		Antagonist 98.98%
    Telcagepant (MK-0974) is an orally active calcitonin gene-related peptide (CGRP) receptor antagonist with Kis of 0.77 nM and 1.2 nM for human and rhesus CGRP receptors, respectively.
    Telcagepant
  • HY-P1071A
    α-CGRP(human) TFA
    		98.44%
    α-CGRP(human) TFA is a regulatory neuropeptide of 37 amino acids. α-CGRP(human) is widely distributed in the central and peripheral nervous system. α-CGRP(human) TFA is a potent vasodilator.
    α-CGRP(human) TFA
  • HY-P9938
    Erenumab
    		Inhibitor
    Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine.
    Erenumab
  • HY-P99019
    Fremanezumab
    		Inhibitor
    Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitonin gene-related peptide (CGRP). CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research.
    Fremanezumab
  • HY-P99021
    Galcanezumab
    		Inhibitor 98.00%
    Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research.
    Galcanezumab
  • HY-10302
    MK-3207 Hydrochloride
    		Antagonist 98.02%
    MK-3207 (Hydrochloride) is a potent and orally bioavailable CGRP receptor antagonist with IC50 of 0.12 nM and Ki of 0.024 nM, and is highly selective versus human AM1, AM2, CTR, and AMY3.
    MK-3207 Hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity